Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 29;11(23):3829.
doi: 10.3390/cells11233829.

Iron Brain Menace: The Involvement of Ferroptosis in Parkinson Disease

Affiliations
Review

Iron Brain Menace: The Involvement of Ferroptosis in Parkinson Disease

Kai-Jung Lin et al. Cells. .

Abstract

Parkinson disease (PD) is the second-most common neurodegenerative disease. The characteristic pathology of progressive dopaminergic neuronal loss in people with PD is associated with iron accumulation and is suggested to be driven in part by the novel cell death pathway, ferroptosis. A unique modality of cell death, ferroptosis is mediated by iron-dependent phospholipid peroxidation. The mechanisms of ferroptosis inhibitors enhance antioxidative capacity to counter the oxidative stress from lipid peroxidation, such as through the system xc-/glutathione (GSH)/glutathione peroxidase 4 (GPX4) axis and the coenzyme Q10 (CoQ10)/FSP1 pathway. Another means to reduce ferroptosis is with iron chelators. To date, there is no disease-modifying therapy to cure or slow PD progression, and a recent topic of research seeks to intervene with the development of PD via regulation of ferroptosis. In this review, we provide a discussion of different cell death pathways, the molecular mechanisms of ferroptosis, the role of ferroptosis in blood-brain barrier damage, updates on PD studies in ferroptosis, and the latest progress of pharmacological agents targeting ferroptosis for the intervention of PD in clinical trials.

Keywords: CoQ10; FSP1; GPX4; Parkinson disease; ferroptosis; glutathione; iron metabolism; lipid peroxidation; lipoxygenase; system xc−.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Regulatory pathways of ferroptosis. The iron metabolism (left) includes the endosomal uptake of ferritin-bound Fe3+, Fe3+ conversion to Fe2+ via STEAP proteins, Fe2+ release through the transporters DMT1 and ZIP8/14, and Fe2+ distribution to different intracellular regions via the chaperones, including PCBP1 and PCBP2. Iron is delivered to the labile iron pool, imported into the mitochondria, stored in ferritin, etc. In low-iron situations, the degradation of ferritin through ferritinophagy occurs and releases the ferritin-bound iron into the cytoplasm. In the case of excess iron, the iron is exported by ferroportin. The mitochondrial ETC generate O2—which is reduced to H2O2 by the antioxidant SOD. The H2O2 under the catalysis of Fe2+ from the labile iron pool participates in the Fenton reaction, creating hydroxyl radicals, which further activates lipid peroxidation, leading to ferroptosis. The system xc/GSH/GPX4 axis (right) exerts antioxidative effects to prevent ferroptosis. Cystine is transported into the cell by system xc and then converted to cysteine, which is a key component of GSH. The reducing activity of GSH keeps GPX4 in its reduced state to maintain the antioxidative abilities of GPX4. GPX4 can directly inhibit lipid peroxidation, therefore inhibiting ferroptosis. Inducers of ferroptosis inhibit system xc, such as erastin and glutamate, or inhibit GPX4, such as RSL3. Inhibitors of ferroptosis include iron chelators, such as deferoxamine, and lipid peroxidation inhibitors, such as CoQ10, ferrostatin-1, and liproxstatin-1.
Figure 2
Figure 2
The mechanisms of lipid peroxidation and chemical formula. Lipid peroxidation involves two pathways, the non-enzymatic pathway and the enzymatic pathway. The non-enzymatic pathway includes three steps: initiation, propagation, and termination. In the initiation step, membrane phospholipids are targeted by radicals, such as the hydroxyl radicals, from the Fenton reaction and form lipid radicals. In the propagation step, O2 added to the lipid radical forms the lipid peroxyl radical and the addition of phospholipid generates lipid hydroperoxide. This forms a loop, creating new lipid peroxyl radicals, and eventually can lead to ferroptosis. In the termination step, antioxidants, such as the system xc/GSH/GPX4 axis and the CoQ10/FSP1 pathway exert, antioxidative effects. GPX4 can directly convert lipid hydroperoxide to lipid alcohol. In the enzymatic pathway, the PUFA is ligated to CoA under ACSL4. LPCAT3 catalyzes PUFA–CoA esterification into PE–PUFA, and the PUFA forms a side chain of the phospholipid. Under the enzyme LOX and the presence of Fe2+, PE–PUFA forms toxic PE–PUFA–OOH, which leads to ferroptosis. Antioxidants work in the same way during termination.

Similar articles

Cited by

References

    1. Poewe W., Seppi K., Tanner C.M., Halliday G.M., Brundin P., Volkmann J., Schrag A.-E., Lang A.E. Parkinson disease. Nat. Rev. Dis. Prim. 2017;3:17013. doi: 10.1038/nrdp.2017.13. - DOI - PubMed
    1. Ascherio A., Schwarzschild M.A. The epidemiology of Parkinson’s disease: Risk factors and prevention. Lancet Neurol. 2016;15:1257–1272. doi: 10.1016/S1474-4422(16)30230-7. - DOI - PubMed
    1. Schapira A.H.V., Chaudhuri K.R., Jenner P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 2017;18:435–450. doi: 10.1038/nrn.2017.62. - DOI - PubMed
    1. Geut H., Hepp D.H., Foncke E., Berendse H.W., Rozemuller J.M., Huitinga I., van de Berg W.D.J. Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series. Acta Neuropathol. Commun. 2020;8:39. doi: 10.1186/s40478-020-00914-9. - DOI - PMC - PubMed
    1. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging. 2003;24:197–211. doi: 10.1016/S0197-4580(02)00065-9. - DOI - PubMed

MeSH terms